Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05955170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Study acronym: TUC-TOC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 19, 2026 to Dec 19, 2027
    • Study completion date: Dec 19, 2027 to Dec 19, 2028
    • Site details revised at 5 of 13 sites
    v8
  2. Study sites: 12 to 13v7
  3. Study sites: 8 to 12v6
  4. Primary completion date: Dec 12, 2026 to Dec 19, 2026
    • Study completion date: Dec 12, 2027 to Dec 19, 2027
    • Start date: Dec 12, 2023 to Dec 19, 2023
    v5
  5. Trial status: Active, Not Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Nov 30, 2026 to Dec 12, 2026
    • Study completion date: Nov 30, 2027 to Dec 12, 2027
    • Start date: Nov 30, 2023 to Dec 12, 2023
    • Site details revised at 8 of 8 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 8
    • Start date changed from estimate of Nov 7, 2023 to Nov 30, 2023
    v3
  2. Primary completion date: Apr 15, 2026 to Nov 30, 2026
    • Start date: Sep 15, 2023 to Nov 7, 2023
    • Study completion date: Dec 15, 2027 to Nov 30, 2027
    • Interventions: Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab) (Drug) to Tucatinib in Combination of Oral VP16 and trastuzumab (Drug)
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.
Trial Details
NCT Number NCT05955170
Lead Sponsor Institut Curie
Collaborators: Seagen Inc.
Conditions
(from sponsor)		 HER2-positive Breast Cancer
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov